JP5284290B2 - ウイルス様粒子の精製 - Google Patents

ウイルス様粒子の精製 Download PDF

Info

Publication number
JP5284290B2
JP5284290B2 JP2009553820A JP2009553820A JP5284290B2 JP 5284290 B2 JP5284290 B2 JP 5284290B2 JP 2009553820 A JP2009553820 A JP 2009553820A JP 2009553820 A JP2009553820 A JP 2009553820A JP 5284290 B2 JP5284290 B2 JP 5284290B2
Authority
JP
Japan
Prior art keywords
vlp
chromatography
vlps
chromatographic
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009553820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530734A (ja
Inventor
ヴェドヴィック,トーマス,エス.
シュテットマン,ブライアン
リチャードソン,チャールズ
フォーベルト,トーマス,アール.
アール. ピートリー,チャールス
Original Assignee
リゴサイト ファーマスーティカルズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リゴサイト ファーマスーティカルズ,インコーポレイテッド filed Critical リゴサイト ファーマスーティカルズ,インコーポレイテッド
Publication of JP2010530734A publication Critical patent/JP2010530734A/ja
Application granted granted Critical
Publication of JP5284290B2 publication Critical patent/JP5284290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009553820A 2007-03-14 2008-03-14 ウイルス様粒子の精製 Active JP5284290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90682107P 2007-03-14 2007-03-14
US60/906,821 2007-03-14
PCT/US2008/057072 WO2008113011A2 (en) 2007-03-14 2008-03-14 Virus like particle purification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112580A Division JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製

Publications (2)

Publication Number Publication Date
JP2010530734A JP2010530734A (ja) 2010-09-16
JP5284290B2 true JP5284290B2 (ja) 2013-09-11

Family

ID=39760420

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009553820A Active JP5284290B2 (ja) 2007-03-14 2008-03-14 ウイルス様粒子の精製
JP2013112580A Pending JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製
JP2017032171A Pending JP2017086090A (ja) 2007-03-14 2017-02-23 ウイルス様粒子の精製
JP2019000688A Pending JP2019068846A (ja) 2007-03-14 2019-01-07 ウイルス様粒子の精製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013112580A Pending JP2013176392A (ja) 2007-03-14 2013-05-29 ウイルス様粒子の精製
JP2017032171A Pending JP2017086090A (ja) 2007-03-14 2017-02-23 ウイルス様粒子の精製
JP2019000688A Pending JP2019068846A (ja) 2007-03-14 2019-01-07 ウイルス様粒子の精製

Country Status (12)

Country Link
US (4) US8481693B2 (cg-RX-API-DMAC7.html)
EP (1) EP2134360B1 (cg-RX-API-DMAC7.html)
JP (4) JP5284290B2 (cg-RX-API-DMAC7.html)
KR (3) KR101576219B1 (cg-RX-API-DMAC7.html)
AU (1) AU2008224877B2 (cg-RX-API-DMAC7.html)
CA (1) CA2683977C (cg-RX-API-DMAC7.html)
DK (1) DK2134360T3 (cg-RX-API-DMAC7.html)
ES (1) ES2559421T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028605T2 (cg-RX-API-DMAC7.html)
PL (1) PL2134360T3 (cg-RX-API-DMAC7.html)
SG (2) SG10201701988TA (cg-RX-API-DMAC7.html)
WO (1) WO2008113011A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025022899A (ja) * 2017-12-07 2025-02-14 エーエムペー・バイオテック・ゲーエムベーハー 応用ラジアル技術クロマトグラフィのシステム及び方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601970B1 (en) 2006-09-29 2016-10-26 Takeda Vaccines, Inc. Norovirus vaccine formulations
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
KR101576219B1 (ko) 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201403290SA (en) * 2009-06-16 2014-10-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
EP2449096A4 (en) * 2009-07-03 2014-01-08 Univ Queensland METHOD FOR PRODUCING A BIOLOGICAL PARTICLE STRUCTURE
US20110142863A1 (en) 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules
US8951807B2 (en) 2010-01-15 2015-02-10 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
SG184833A1 (en) * 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
WO2012106449A1 (en) 2011-02-02 2012-08-09 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
BR112014000656A2 (pt) * 2011-07-11 2017-02-14 Takeda Vaccines Inc formulações de vacina parenteral contra norovírus
EP2554664A1 (de) * 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
JP2015503915A (ja) * 2011-12-30 2015-02-05 ドイチェス クレブスフォルシュンクスツェントルム ワクチン接種目的のためのエプスタイン・バーウイルス由来の第二世代ウイルス様粒子(vlp)
WO2013180933A1 (en) 2012-05-30 2013-12-05 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014129964A2 (en) * 2013-02-22 2014-08-28 Agency For Science, Technology And Research Chromatographic purification of virus preparations with negatively charged particles
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Umnファーマ ウイルス様粒子の精製方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
EP3052631B1 (en) 2013-10-03 2019-08-07 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
WO2015200299A2 (en) 2014-06-23 2015-12-30 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
EP3157689B1 (en) 2014-06-23 2021-04-28 Bio-Rad Laboratories, Inc. Apatite pretreatment
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Umnファーマ ウイルス様粒子の精製方法
EP3995504A4 (en) * 2019-07-04 2023-07-12 Kaneka Corporation PROCEDURE FOR PURIFICATION OF VIRUS OR VIRUS-LIKE PARTICLES
EP4206329A4 (en) * 2020-08-28 2024-11-20 Kaneka Corporation Method for purifying useful substance
WO2022073995A1 (en) * 2020-10-05 2022-04-14 Bia Separations D.O.O. Improved removal of rna and contaminants from dna plasmid preparations by hydrophobic interaction chromatography
WO2022168730A1 (ja) * 2021-02-02 2022-08-11 株式会社ニチモ 太陽光発電システム及び太陽光発電システム用反射体
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
WO2025077800A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Purification of norovirus virus-like particles (vlps)
WO2025077807A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Methods for obtaining high-purity norovirus virus-like particles (vlps)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2189882C (en) * 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU738585B2 (en) 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
DK1015561T3 (da) * 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
DE19823814A1 (de) * 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
EA200100236A1 (ru) * 1998-08-14 2001-08-27 Мерк Энд Ко., Инк. Способ очистки вирусных частиц, подобных вирусу папилломы человека
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
US7067638B1 (en) * 1999-06-22 2006-06-27 Japan As Represented By Director-General National Institute Of Infectious Diseases Small round structured virus (SRSV) detection kit
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
AU2003213060A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US8277819B2 (en) * 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP5215865B2 (ja) * 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
BRPI0620859A2 (pt) 2005-12-29 2011-11-22 Boehringer Ingelheim Vetmedica, Inc. vacina de combinação multivalente contra pcv2
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
EP2601970B1 (en) * 2006-09-29 2016-10-26 Takeda Vaccines, Inc. Norovirus vaccine formulations
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
KR101576219B1 (ko) 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
EP2235165A1 (en) 2007-12-21 2010-10-06 Cytos Biotechnology AG Process for clarifying cell homogenates
SG2013057732A (en) * 2008-08-08 2015-02-27 Ligocyte Pharmaceuticals Inc Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010062757A1 (en) 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
AU2011207355B2 (en) * 2010-01-21 2015-04-02 Takeda Vaccines, Inc. Targeted heterologous antigen presentation on Calicivirus virus-like particles
JP5903101B2 (ja) 2010-09-20 2016-04-13 バイオ−ラッド ラボラトリーズ インコーポレーティッド クロマトグラフィーにおける生成物と複合体形成した夾雑物の分離方法
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025022899A (ja) * 2017-12-07 2025-02-14 エーエムペー・バイオテック・ゲーエムベーハー 応用ラジアル技術クロマトグラフィのシステム及び方法

Also Published As

Publication number Publication date
KR20170001720A (ko) 2017-01-04
CA2683977A1 (en) 2008-09-18
EP2134360A2 (en) 2009-12-23
JP2013176392A (ja) 2013-09-09
US8481693B2 (en) 2013-07-09
AU2008224877B2 (en) 2013-07-11
CA2683977C (en) 2017-04-25
KR101576219B1 (ko) 2015-12-10
US10792353B2 (en) 2020-10-06
AU2008224877A1 (en) 2008-09-18
US20190282686A1 (en) 2019-09-19
HK1138795A1 (zh) 2010-09-03
EP2134360A4 (en) 2011-08-24
PL2134360T3 (pl) 2016-05-31
KR20100015562A (ko) 2010-02-12
DK2134360T3 (en) 2016-02-22
SG10201701988TA (en) 2017-04-27
JP2010530734A (ja) 2010-09-16
WO2008113011A2 (en) 2008-09-18
JP2019068846A (ja) 2019-05-09
KR20150098681A (ko) 2015-08-28
US20160317645A1 (en) 2016-11-03
US20100150961A1 (en) 2010-06-17
US9359410B2 (en) 2016-06-07
WO2008113011A3 (en) 2008-12-24
US20130344107A1 (en) 2013-12-26
ES2559421T3 (es) 2016-02-12
US10172930B2 (en) 2019-01-08
SG179488A1 (en) 2012-04-27
EP2134360B1 (en) 2015-11-18
JP2017086090A (ja) 2017-05-25
HUE028605T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
JP5284290B2 (ja) ウイルス様粒子の精製
Li et al. A hydrophobic interaction chromatography strategy for purification of inactivated foot-and-mouth disease virus
US10570376B2 (en) Method for influenza virus purification
JP2007523621A (ja) ウイルスを精製するための方法
JP7540667B2 (ja) アデノウイルス精製の方法
Chen et al. Purification of capsid-like particles of infectious bursal disease virus (IBDV) VP2 expressed in E. coli with a metal-ion affinity membrane system
AU2013242822B2 (en) Virus like particle purification
JP7586936B2 (ja) 混入dnaをより効果的に除去するための、アデノ随伴ウイルスの精製の強化
AU2016269506A1 (en) Virus like particle purification
HK1138795B (en) Virus like particle purification
JP2024004020A (ja) A型肝炎ウイルスのクロマトグラフィー精製方法
JP4706093B2 (ja) パルボウイルスの除去方法及び精製方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130529

R150 Certificate of patent or registration of utility model

Ref document number: 5284290

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250